Combining methionine‐PET and MRI fluid‐attenuated inversion‐recovery mismatch to determine glioma molecular subtype

11C‐methionine (MET)‐PET is a useful tool in neuro‐oncology. The T2‐fluid‐attenuated inversion recovery (FLAIR) mismatch sign on MRI is a characteristic finding in lower grade gliomas with isocitrate dehydrogenase (IDH) mutations and the absence of the 1p/19q codeletion; however, the T2‐FLAIR mismatch sign has low sensitivity in differentiating gliomas and does not aid in identifying glioblastomas with IDH mutations. We therefore investigated the efficacy of the combination of the T2‐FLAIR mismatch sign and MET‐PET for accurately determining the molecular subtype of gliomas of all grades.

[1]  T. Iwaya,et al.  PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma , 2022, Clinical nuclear medicine.

[2]  Yuichi Fujita,et al.  NI-7 Diffusion-weighted imaging for monitoring acute response and recurrence after photodynamic therapy in malignant gliomas , 2021, Neuro-oncology Advances.

[3]  R. Taipa,et al.  T2-FLAIR mismatch sign: a roadmap of pearls and pitfalls. , 2021, The British journal of radiology.

[4]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[5]  M. Scorsetti,et al.  Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study , 2021, Journal of clinical medicine.

[6]  N. Nakayama,et al.  Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system. , 2020, Journal of neurosurgery.

[7]  S. Thust,et al.  Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review , 2020, Neuroradiology.

[8]  Zhi-rui Zhou,et al.  A Nomogram Modeling 11C-MET PET/CT and Clinical Features in Glioma Helps Predict IDH Mutation , 2020, Frontiers in Oncology.

[9]  A. Shinomiya,et al.  Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification , 2020, EJNMMI Research.

[10]  Sohil H. Patel,et al.  'Real world' use of a highly reliable imaging sign: 'T2-FLAIR mismatch' for identification of IDH mutant astrocytomas. , 2020, Neuro-oncology.

[11]  S. Heiland,et al.  T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology , 2020, Neuro-oncology advances.

[12]  P. Kerezoudis,et al.  The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. , 2019, Neurosurgical focus.

[13]  Sohil H. Patel,et al.  T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project , 2017, Clinical Cancer Research.

[14]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[15]  Pankaj Pathak,et al.  Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. , 2013, Neuro-oncology.

[16]  Akira Matsumura,et al.  Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing , 2011, Brain Tumor Pathology.

[17]  Y. Muragaki,et al.  Metabolic Assessment of Gliomas Using 11C-Methionine, [18F] Fluorodeoxyglucose, and 11C-Choline Positron-Emission Tomography , 2008, American Journal of Neuroradiology.

[18]  I Kapouleas,et al.  Registration of three-dimensional MR and PET images of the human brain without markers. , 1991, Radiology.

[19]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[20]  J. Mukherjee,et al.  11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas , 2007, Molecular Imaging and Biology.